Zoetis Inc. $ZTS Holdings Raised by Ascent Group LLC

Ascent Group LLC boosted its stake in Zoetis Inc. (NYSE:ZTS) by 18.8% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 26,276 shares of the company’s stock after buying an additional 4,158 shares during the quarter. Ascent Group LLC’s holdings in Zoetis were worth $4,326,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Portside Wealth Group LLC lifted its position in Zoetis by 24.7% in the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company’s stock worth $5,550,000 after buying an additional 6,672 shares in the last quarter. Tandem Investment Advisors Inc. lifted its position in Zoetis by 100.3% in the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company’s stock worth $65,140,000 after buying an additional 198,089 shares in the last quarter. Flagship Harbor Advisors LLC lifted its position in Zoetis by 31.2% in the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company’s stock worth $1,217,000 after buying an additional 1,760 shares in the last quarter. Horizon Financial Services LLC purchased a new stake in Zoetis in the 1st quarter worth approximately $380,000. Finally, Sage Rhino Capital LLC lifted its position in Zoetis by 117.6% in the 1st quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company’s stock worth $1,155,000 after buying an additional 3,791 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $151.88 on Tuesday. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The firm’s fifty day simple moving average is $153.08 and its 200 day simple moving average is $157.67. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The firm has a market capitalization of $67.31 billion, a PE ratio of 26.14, a PEG ratio of 2.46 and a beta of 0.88.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same period last year, the business posted $1.56 EPS. Zoetis’s revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and dropped their price target for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Piper Sandler increased their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Finally, Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $202.43.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.